Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Half a century of women prime ministers; still no Pharma CEO

This article was originally published in Scrip

Executive Summary

Margaret Thatcher, ‘The Iron Lady' who was prime minister of the UK from 1979-1990 and Europe's first female elected ruler, died 8 April aged 87. Not all will mourn Mrs Thatcher, but her death comes as a reminder that running countries has been acceptable women’s work for some time: since 1960, at least 55 women have fought for and won the top job in politics across all continents. But as yet, no top 20 pharma firm appears to be as trusting as the gender-neutral electorates of countries such as the UK, India, Pakistan, South Korea, Haiti, Jamaica or Mongolia.

You may also be interested in...

Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts